Julian Harrison
Stock Analyst at BTIG
(1.01)
# 3,697
Out of 4,884 analysts
38
Total ratings
31.25%
Success rate
-13.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBPH Theravance Biopharma | Maintains: Buy | $24 → $25 | $11.15 | +124.22% | 2 | Jun 27, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $40 | $4.96 | +706.45% | 1 | Dec 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $42 | $11.21 | +274.67% | 1 | Dec 19, 2024 | |
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $13.45 | - | 3 | Dec 12, 2024 | |
| ANAB AnaptysBio | Downgrades: Neutral | n/a | $23.75 | - | 2 | Dec 2, 2024 | |
| OTLK Outlook Therapeutics | Maintains: Buy | $50 → $9 | $1.78 | +405.62% | 5 | Nov 29, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Buy | $8 | $1.44 | +455.56% | 4 | Nov 19, 2024 | |
| VYNE VYNE Therapeutics | Initiates: Buy | $8 | $1.43 | +461.40% | 1 | Nov 18, 2024 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $56 → $61 | $15.67 | +289.28% | 3 | Sep 26, 2024 | |
| RZLT Rezolute | Maintains: Buy | $13 → $15 | $4.82 | +211.20% | 2 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $25 | $12.19 | +105.09% | 3 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $41 → $51 | $51.05 | -0.10% | 2 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $7.96 | +440.20% | 1 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $40 | $15.76 | +153.81% | 2 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $47.46 | -9.40% | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $4 | $3.62 | +10.50% | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $150 | $0.92 | +16,254.12% | 1 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $48.89 | -26.37% | 1 | Mar 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $294.49 | - | 2 | Feb 11, 2022 | |
Theravance Biopharma
Jun 27, 2025
Maintains: Buy
Price Target: $24 → $25
Current: $11.15
Upside: +124.22%
Avalo Therapeutics
Dec 19, 2024
Initiates: Buy
Price Target: $40
Current: $4.96
Upside: +706.45%
Cartesian Therapeutics
Dec 19, 2024
Initiates: Buy
Price Target: $42
Current: $11.21
Upside: +274.67%
Keros Therapeutics
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $13.45
Upside: -
AnaptysBio
Dec 2, 2024
Downgrades: Neutral
Price Target: n/a
Current: $23.75
Upside: -
Outlook Therapeutics
Nov 29, 2024
Maintains: Buy
Price Target: $50 → $9
Current: $1.78
Upside: +405.62%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Buy
Price Target: $8
Current: $1.44
Upside: +455.56%
VYNE Therapeutics
Nov 18, 2024
Initiates: Buy
Price Target: $8
Current: $1.43
Upside: +461.40%
Viridian Therapeutics
Sep 26, 2024
Maintains: Buy
Price Target: $56 → $61
Current: $15.67
Upside: +289.28%
Rezolute
Sep 10, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $4.82
Upside: +211.20%
Aug 20, 2024
Maintains: Buy
Price Target: $29 → $25
Current: $12.19
Upside: +105.09%
Jul 24, 2024
Maintains: Buy
Price Target: $41 → $51
Current: $51.05
Upside: -0.10%
May 20, 2024
Initiates: Buy
Price Target: $43
Current: $7.96
Upside: +440.20%
May 10, 2024
Maintains: Buy
Price Target: $32 → $40
Current: $15.76
Upside: +153.81%
Dec 20, 2023
Initiates: Buy
Price Target: $43
Current: $47.46
Upside: -9.40%
Nov 29, 2023
Assumes: Buy
Price Target: $4
Current: $3.62
Upside: +10.50%
Oct 11, 2023
Reinstates: Buy
Price Target: $150
Current: $0.92
Upside: +16,254.12%
Mar 9, 2023
Initiates: Buy
Price Target: $36
Current: $48.89
Upside: -26.37%
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $294.49
Upside: -